Translational efforts face challenges—particularly the non‐specific effects of glucocorticoids—but future development of selective DUSP1 enhancers or allosteric activators, combined with biomarker‐guided patient stratification, may enable precise targeting of inflammatory and stress pathways in MDD, advancing beyond conventional monoamine‐based therapeutics. This evidence concerns the gene DUSP1 and major depressive disorder.